Medical Watch Disease & Treatment News

• Type 2 inflammation occurs in 20%–40% of COPD patients, identified by elevated blood eosinophils, FeNO, and IL-4/IL-13 activation
• Dupilumab cuts...

• Live human brain slices from neurosurgery and monocyte-derived microglia revealed P2X7 receptor blockade suppresses cytokine release via NLRP3...

Current quality control methods for cell and gene therapies fall short by averaging data across cell populations.

• Bulk NGS and ddPCR mask whether...

The post-antibiotic era has arrived, with drug-resistant infections now claiming 1.27 million lives directly each year and P. aeruginosa listed as a...

Precision oncology is shifting from matching genetic mutations to drugs toward deeper pathway biology and structural mechanisms that make previously...

• PFS Edge: PVR cut progression/death risk 45% vs VR (HR 0.547), with 24-month PFS 86.9% vs 71.8%.
• High-Risk Gains: TP53/del(17p) patients saw...

A new clinical trial is testing bexmarilimab to potentially reverse resistance to immunotherapy in lung cancer and melanoma. This marks promising early-stage activity with no established patient benefit yet reported.

• Benefits claimed: FDA-approved inhibitors slow GA progression 21% with monthly dosing, potentially preserving vision and independence longer
  -...

Advances in screening and amyloid imaging are identifying more patients for anti-amyloid therapy, yet eligibility questions and evidence gaps...

A new study examines how patient age influences immune-related adverse events and survival outcomes with immune checkpoint inhibitors in non-small...

Plasma APOE4 protein levels accurately classify ε4 carrier status and copy number while matching DNA genotyping's AD associations.

• High accuracy:...

APOE4 reduces TAGLN3 in human iPSC-derived astrocytes, locking them into heightened inflammatory NF-κB signaling across the Alzheimer’s spectrum. Restoring TAGLN3 or related pharmacological approaches may reopen protective signaling pathways.

Real-world evidence supports pembrolizumab as an effective chemotherapy-free option for dMMR/MSI-H advanced or recurrent endometrial cancer. Confirmatory comparative data remain essential to validate these findings.

Nifedipine suppresses amyloid fibril assembly and reduces biofilm biomass in the resistant MRSA T144 strain, highlighting its potential as a repurposed dual-function adjuvant.

Two innovative platforms are addressing gaps in traditional flu shots by boosting mucosal responses and overall efficacy.

• Protein-nanoparticle...

Large-scale prescription data from routine care platforms are vital for tracking community antibiotic use and resistance outside hospitals.

• 10.8% of...

Self-adaptive RNA therapeutics are emerging as a credible bridge from preventive vaccination to on-demand treatment, with the first saRNA vaccine...

Positive Phase 3 results for intismeran autogene in melanoma mark a clinical milestone for Moderna's mRNA platform in oncology.

• Clinical side: Data...

A 71-year-old ES-SCLC patient developed sequential myocarditis, myositis, hepatic injury, then hypophysitis with hypothyroidism and adrenal failure...

Can pembrolizumab plus chemotherapy improve outcomes in PD-L1-positive, endocrine-resistant HR+/HER2- metastatic breast cancer?

The phase III...